2024828Other
取締役COOの安井季久央が、Stimuliverのアドバイザーに就任しました。
Stimuliver（本社:？デンマーク、CEO: David Hay）は、肝臓病の治療法として多能性幹細胞から作製した肝臓オルガノイドを開発している非臨床ステージのバイオテック企業で、治験開始に向けて準備を進めています。安井は事業開発活動の一環として国内外のバイオテック企業と面談を重ねる中で、開発ステージは早期ながらも同社の再生医療の可能性に期待を寄せていました。今後安井は、Heartseedでの業務に支障を来さない範囲で、これまでの経験を活かし、Stimuliverの取締役会に対して助言を行ってまいります。
詳細はStimuliverからのメッセージをご参照ください：
Stimuliver welcomes Kikuo Yasui, COO of Heartseed Inc., as a Board Advisor
Copenhagen, Denmark, 2024 - Stimuliver APS, an innovative biotech company developing a first-in-class tissue implant to treat acute and chronic liver diseases, is excited to announce a new addition to our Board of Advisors.
We are honored to welcome Kikuo Yasui to the Stimuliver team!
Kikuo Yasui is a seasoned leader in the biotech industry, with extensive experience in cell therapy. As COO of Heartseed Inc., Kikuo has been key in driving the company’s evolution from an early-stage biotech to its successful listing on the Tokyo Stock Exchange (TSE). His leadership in building strategic partnerships and fostering innovation has positioned Heartseed as a leader in cardiac regeneration.
At Stimuliver, we are pioneering the development of multi-cellular organoids to create breakthrough treatments for liver diseases. Kikuo’s proven track record in cell therapy and his strong connections within the Asian biotech ecosystem, particularly in Japan, will be invaluable as we expand our reach and partnerships.
"I am delighted to join Stimuliver as a Board Advisor. The team has made significant strides in liver disease treatment, and I look forward to contributing my experience to help advance Stimuliver’s mission," said Kikuo Yasui.
"Having Kikuo as an advisor strengthens our team immensely. His insights and experience will be critical as we continue to grow and develop innovative solutions for liver diseases," said Prof. David Hay, CEO & co-founder.
Stimuliver is a Danish biotech company rooted in technology from The University of Edinburgh, dedicated to developing a scalable, safe, and effective treatment for liver diseases. Our first-in-class, vascularized, and immunomodulatory liver tissue implant aims to address both acute and chronic liver conditions, providing new hope where treatment options are currently limited. Stimuliver is supported by BioInnovation Institute, Export and Investment Fund of Denmark, Old College Capital, and Innovation Fund Denmark.
